Parkinson's clinical study

About the study

This research project is designed to test the safety, tolerability, and the effect on movement and pharmacokinetics (how the body processes the study treatment) of an experimental treatment called INP103. INP103 is a medication-device combination product being developed for the potential treatment of Parkinson’s disease. Specifically, for patients who are experiencing “wearing off” of their usual L-dopa treatment.

Who can participate

We are looking for  patients diagnosed with Idiopathic Parkinson's with Modified Hoehn & Yahr (H&Y) Stage I-III and who are currently on L-dopa containing medication.

If you match the minimum eligibility criteria then please sign up below to receive more information about this study or call us now on 1300 774 276 and one of our staff members will go through the study in more detail.

If you are eligible to enter the study, you will be reimbursed $535 for the screening, dopamine response and follow-up visits.  You will also be reimbursed for your travel.

To be eligible you must:

  • Be aged between 40-80 years

  • Be diagnosed with Idiopathic PD with Modified Hoehn & Yahr (H&Y) Stage I-III

  • Currently be taking L-Dopa containing medication

  • Be available for 4 visits to our clinic in Herston, Brisbane

This study involves:

qicon-day_visit_blue_sm

0

DAY VISITS

Clinic location